Zhongheng Group (600252.SH) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd., a holding subsidiary of the company (...
Zhitong Finance App News, Zhongheng Group (600252.SH) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd. (hereinafter referred to as “Laimei Pharmaceutical”), a holding subsidiary of the company, received the approval and issuance of the “Drug Supplement Application Approval Notice” for injectable esomeprazole sodium (specification: 20mg) by the State Drug Administration.
According to reports, Lemay Pharmaceuticals obtained a “Drug Registration Certificate” with a specification of 40 mg of esomeprazole sodium for injection in December 2020. This time, Lemei Pharmaceuticals obtained the “Drug Supplement Application Approval Notice” for injectable esomeprazole sodium (specification: 20 mg), which can better meet the different clinical dosage requirements.